Unfortunately, in some tumors, including medulloblastoma, glioma, pericytoma, prostate, and breast cancer, there are many alternative mechanisms for HH signaling activation through Smo downstream effectors, making Smo inhibitors ultimately ineffective. The gene discussed is SMO; the disease is central nervous system cancer.